Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorHospital de Clinicas de Porto Alegre
About this trial
Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.
Eligibility criteria
Qualifiers
White Brazilian of European descent
Fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria for ADHD
Eligibility to immediate-release MPH (IR-MPH) treatment
Disqualifiers
Contraindication for IR-MPH use
Current stimulant treatment
Evidence of a clinically significant neurological disease that might affect cognition (e.g., delirium, dementia, epilepsy, head trauma, and multiple sclerosis)
Current or past history of psychosis
Trial design
Treatments tested in this trial
- Immediate-release Methylphenidate
Treatment groups
600 Participants
are divided into 1 treatment groupSponsors and collaborators
Hospital de Clinicas de Porto Alegre
Lead sponsor
Federal University of Rio Grande do Sul
Collaborator
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Collaborator
Coordination for the Improvement of Higher Education Personnel
Collaborator
Source ClinicalTrials.gov